Literature DB >> 7163807

[Specific scintigraphy in pheochromocytoma].

M Fischer, B Winterberg, J Hengstmann, H Vetter.   

Abstract

In 5 patients with pheochromocytoma and 1 patient with a pheochromoblastoma, 131I-meta-iodobenzylguanidine was used to localize hyperfunktioning adrenergic tissue. Except in one patient, a correct localization of the tumors was obtained. Three patients had an intraadrenal pheochromocytoma of the left adrenal gland, 1 patient a retropancreatic pheochromoblastoma and 1 patient multilocular pheochromocytoma with tumors in both renal hili, in the supraclavicular region and in the bones. In one patient with a pheochromocytoma of the right adrenal, no clearcut visualization of the tumor could be observed. In this patient, in contrast to the other examinations, a specific activity of 2 mCi/mg benzylguanidine was used (0.2 mCi/mg benzylguanidine in the other patients). Thus, the amount of benzylguanidine given for each scan was 10fold higher in the patients with a correct localization. The present results document the claim that scintigraphy with 131I-benzylguanidine is a safe and reliable method of detecting both benign and malignant adrenal and extra-adrenal pheochromocytoma. To separate the pheochromocytoma from the adjacent tissue, additional computed tomography should be performed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7163807

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  1 in total

1.  Comparison of 131I-metaiodobenzylguanidine scintigraphy with urinary and plasma catecholamine determinations in the diagnosis of pheochromocytoma.

Authors:  G Plewe; J Beyer; U Krause; U Cordes; D Eissner; K Hahn
Journal:  Klin Wochenschr       Date:  1985-07-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.